AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

Group 1: Investment Potential - AstraZeneca PLC is ranked fourth in a list of the Top 10 Oncology Stocks to Buy Now, indicating strong investment interest in the company [1] - Barclays analyst James Gordon raised the price target for AstraZeneca from 14,000 GBp to 16,500 GBp, maintaining an Overweight rating on the shares, suggesting positive market sentiment [1] Group 2: Clinical Developments - AstraZeneca announced significant results from its Phase III TULIP‑SC trial of Saphnelo (anifrolumab) for systemic lupus erythematosus (SLE), with 56.2% of patients showing improvement compared to 37.1% in the placebo group, highlighting the drug's potential as a therapy for SLE [2] - The company is advancing cancer care through a robust late-stage oncology pipeline and innovative therapies, aiming to improve patient outcomes across various tumor types globally [3]